LATEST NEWS: 29 July 2026 TROG Cancer Research is set to launch a potentially ground-breaking breast cancer radiation therapy trial in Australia, after the project received a $2.86 million Medical Research Future Fund (MRFF) grant – TROG’s largest ever single grant for a clinical trial. The TROG 24.08 FAST-Forward
LATEST NEWS: 22 June 2026 In an important step toward improving outcomes for people with advanced lung cancer, TROG is set to launch a new international trial testing a novel radiation therapy approach for Australia’s deadliest cancer. The TROG 21.10/TOGA 20-005 PRIME-Lung (Primary Radiotherapy in Metastatic Lung) trial, which
LATEST NEWS: 31 March 2026 TROG’s inaugural Secondary Data Analysis (SDA) grant has been awarded to an early-career researcher who will draw on data from a TROG trial of radiation therapy for prostate cancer to gain a better understanding of long-term patient outcomes. Dr Therese Kang, a Radiation Oncologist
LATEST NEWS: 24 February 2026 The first Australian participant has been recruited to take part in an innovative trial that could mark a shift in how radiation therapy is delivered in lung cancer. Led by Professor Paul Keall, Director of the Image X Institute at the University of Sydney
LATEST NEWS; 26 November 2025 Medical physics researcher and TROG Member Professor Paul Keall has been honoured with two prestigious Premier’s Awards, recognising excellence and innovation in research in cancer imaging and radiation therapy technology, including in TROG clinical trials. Prof Keall was this month named: Congratulations to Prof
LATEST NEWS: 23 October 2025 TROG Cancer Research has opened the new Australian arm of an international trial aimed at preventing skin cancer recurrence, following a groundbreaking collaboration with the US cancer clinical trials group, NRG Oncology. The NRG-HN014 trial is a phase III clinical trial targeting patients with
LATEST NEWS: 24 September 2025 TROG is set to open the Australian arm of an international trial that aims to change practice in the treatment of high-risk prostate cancer, after the research team was awarded a $1.9 million Medical Research Future Fund (MRFF) Clinical Trials Activity grant. Marking a
TRIAL UPDATE: 12 August 2025 Treating inoperable kidney cancer with Stereotactic Ablative Body Radiotherapy (SABR) is both more effective and less expensive than traditional ablative therapies in Australia, according to a new economic analysis of TROG 15.03/ANZUP 16001 FASTRACK II trial data. The findings of the economic evaluation, published
TRIAL IN FOCUS: 29 July 2025 We’ve extended the TROG 21.07 SOCRATES HCC trial recruitment period and are now seeking participants for the trial which could provide evidence for a new and more effective treatment option for patients with early-stage hepatocellular carcinoma (HCC). While curative surgical options are recommended
TRIAL UPDATE: 29 July 2025 A large international study focusing on radiation therapy for ductal carcinoma in situ (DCIS) of the breast has reached a significant milestone, with the database locked this month, 18 years after the first trial site was opened for recruitment. The randomised phase III study
